Ascendis Pharma A (ASND) Income from Non-Controlling Interests (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Income from Non-Controlling Interests data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 4638.07% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $77544.5 (down 92.19% YoY), and the FY2024 full-year result was $1.1 million, up 138.91% from the prior year.
• Income from Non-Controlling Interests grew to $3.6 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $3.6 million in Q1 2026 to a low of -$2.2 million in Q3 2022.
• A 5-year average of -$126456.5 and a median of -$31369.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests slumped 9903.63% in 2025 and soared 4638.07% in 2026, its largest moves.
• Tracing ASND's Income from Non-Controlling Interests over 5 years: stood at $2.3 million in 2022, then plunged by 171.45% to -$1.6 million in 2023, then surged by 155.03% to $886934.2 in 2024, then slumped by 307.47% to -$1.8 million in 2025, then surged by 294.56% to $3.6 million in 2026.
• Business Quant data shows ASND's Income from Non-Controlling Interests at $3.6 million in Q1 2026, -$1.8 million in Q3 2025, and -$1.6 million in Q2 2025.